Terbium-161 PSMA therapy in mCRPC patient based on an optimized radiolabeling protocol

IF 1.6 3区化学 Q3 CHEMISTRY, ANALYTICAL

Journal of Radioanalytical and Nuclear Chemistry Pub Date : 2025-09-01 DOI:10.1007/s10967-025-10352-3

Ceren Sezgin, Emre Uygur, Yasemin Parlak, Busra Karatay, Sabri Barutca, Ahmet Dirican, Tevfik Sinan Sozen, Guven Arslan, Coskun Harmansah, Turkay Toklu, Ugur Avcibasi, Zumrut Biber Muftuler, Omer Aras, Gul Gumuser

{"title":"Terbium-161 PSMA therapy in mCRPC patient based on an optimized radiolabeling protocol","authors":"Ceren Sezgin, Emre Uygur, Yasemin Parlak, Busra Karatay, Sabri Barutca, Ahmet Dirican, Tevfik Sinan Sozen, Guven Arslan, Coskun Harmansah, Turkay Toklu, Ugur Avcibasi, Zumrut Biber Muftuler, Omer Aras, Gul Gumuser","doi":"10.1007/s10967-025-10352-3","DOIUrl":null,"url":null,"abstract":"<div><p>This study presents a novel radiolabeling technique for [<sup>161</sup>Tb]-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC). The research focused on assessing the radiochemical yield, in vivo stability, and pharmacokinetics of [<sup>116</sup> Tb]-PSMA-617 in a clinical setting. Using a sodium acetate buffer and ascorbic acid, a high radiochemical yield (97.98% ± 2.01) was achieved, ensuring stability and purity. The therapy was evaluated to a 77-year-old mCRPC patient resistant to [177Lu]-PSMA-617, showing favorable biodistribution and urinary excretion. Despite initial stability, disease progression occurred, with a TP53 mutation identified via liquid biopsy. While the method holds promise for targeted radionuclide therapy, resistance mechanisms remain a challenge, necessitating further research for optimized patient selection and treatment strategies.</p></div>","PeriodicalId":661,"journal":{"name":"Journal of Radioanalytical and Nuclear Chemistry","volume":"334 9","pages":"5979 - 5988"},"PeriodicalIF":1.6000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Radioanalytical and Nuclear Chemistry","FirstCategoryId":"92","ListUrlMain":"https://link.springer.com/article/10.1007/s10967-025-10352-3","RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, ANALYTICAL","Score":null,"Total":0}

引用次数: 0

Abstract

This study presents a novel radiolabeling technique for [¹⁶¹Tb]-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC). The research focused on assessing the radiochemical yield, in vivo stability, and pharmacokinetics of [¹¹⁶ Tb]-PSMA-617 in a clinical setting. Using a sodium acetate buffer and ascorbic acid, a high radiochemical yield (97.98% ± 2.01) was achieved, ensuring stability and purity. The therapy was evaluated to a 77-year-old mCRPC patient resistant to [177Lu]-PSMA-617, showing favorable biodistribution and urinary excretion. Despite initial stability, disease progression occurred, with a TP53 mutation identified via liquid biopsy. While the method holds promise for targeted radionuclide therapy, resistance mechanisms remain a challenge, necessitating further research for optimized patient selection and treatment strategies.

Abstract Image

查看原文本刊更多论文

基于优化放射标记方案的mCRPC患者terbier161psma治疗

本研究提出了一种新的转移性去势抵抗性前列腺癌（mCRPC） [161Tb]-PSMA-617放射性标记技术。该研究的重点是在临床环境中评估[116 Tb]-PSMA-617的放射化学产率、体内稳定性和药代动力学。使用醋酸钠缓冲液和抗坏血酸，获得了较高的放化产率（97.98%±2.01），保证了稳定性和纯度。对一名77岁mCRPC患者进行了该疗法的评估，该患者对[177Lu]-PSMA-617耐药，显示出良好的生物分布和尿排泄。尽管最初稳定，但疾病发生进展，通过液体活检发现TP53突变。虽然该方法有望用于靶向放射性核素治疗，但耐药机制仍然是一个挑战，需要进一步研究以优化患者选择和治疗策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Radioanalytical and Nuclear Chemistry 化学-分析化学

CiteScore

2.80

自引率

18.80%

发文量

504

审稿时长

2.2 months

期刊介绍： An international periodical publishing original papers, letters, review papers and short communications on nuclear chemistry. The subjects covered include: Nuclear chemistry, Radiochemistry, Radiation chemistry, Radiobiological chemistry, Environmental radiochemistry, Production and control of radioisotopes and labelled compounds, Nuclear power plant chemistry, Nuclear fuel chemistry, Radioanalytical chemistry, Radiation detection and measurement, Nuclear instrumentation and automation, etc.